PAR Drugs and Chemicals posts 730% Q3 profit surge as revenue jumps 37%

PAR Drugs and Chemicals delivered a strong quarter for the period ending December 2025, characterized by a massive spike in profitability and robust top-line growth.

• Quarterly Revenue: Sales jumped 37% year-on-year to ₹2,933.95 million, signaling a significant uptick in demand for the company's products during the December 2025 quarter.
• Net Profit (PAT): Bottom-line performance surged by an extraordinary 730%, reaching ₹479.72 million, up from the same quarter last year. This dramatic turnaround highlights significantly improved earnings power.
• Earnings Per Share (EPS): Basic EPS for the quarter climbed to ₹3.90, a sharp increase from the ₹0.47 reported in the year-ago period.
• Nine-Month Performance: For the first nine months of FY 2025-26, the company maintained a steady trajectory with revenue of ₹8,404.48 million (up 6.9%) and a net profit of ₹1,225.49 million (up 4.7%).
• Operational Highlights: The company reported high governance standards, resolving all three investor complaints received during the period. Additionally, the board updated its related-party transaction policy to align with the latest regulatory guidance.
• Regulatory Standing: A limited review of the results found no material misstatements, and the company confirmed that the insider-trading window will remain closed until 48 hours after the results are publicized.